Navigate the Curis CRIS Stock Research Pages
Introduction - general company overview, financials, pipeline snapshot, upcoming catalysts
ERIVEDGE (vismodegib) - FDA-approved Hedgehog inhibitor partnered with Roche/Genentech for cancer
CUDC-101 - Phase 1 multi-targeted cancer drug candidate
Debio0932 - Phase 1/2 HSP90 inhibitor partnered with Debiopharm for oncology
ERIVEDGE (vismodegib) - FDA-approved Hedgehog inhibitor partnered with Roche/Genentech for cancer
CUDC-101 - Phase 1 multi-targeted cancer drug candidate
Debio0932 - Phase 1/2 HSP90 inhibitor partnered with Debiopharm for oncology
CUDC-101
- Multi-targeted cancer drug candidate wholly owned by Curis
- All slides below from March 2012 investor presentation slide deck unless otherwise specified